This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA

Brian Vastag

JAMA. 2002;288:2397.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In a significant proof-of-concept test, the emerging technology of proteomics has shown its potential by distinguishing prostate cancer from benign prostate conditions, according to a report from the Food and Drug Administration (FDA) and the National Cancer Institute (NCI). The test, which has been in development for 4 years, analyzes protein patterns in a drop of blood, and appears to be more sensitive than the prostate-specific antigen (PSA) test, at least in men with marginally elevated PSA readings, said senior NCI Scientist Lance Liotta, MD, PhD.

Although still under evaluation, the technique could obviate prostate biopsies in men with PSA readings in the gray range of 4 to 10 ng/mL, said Liotta. Currently, 70% to 75% of men who undergo biopsy after PSA testing are found not to have cancer.

Artificial intelligence software was programmed to recognize protein patterns in reference samples from 56 patients who had had . . . [Full Text of this Article]